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It is well known that the circadian clock 
system coordinates physiological functions 
throughout the day (Dibner et al., 2010; Mo-
hawk et al., 2012; Fu and Lee, 2003; Ham-
mad et al., 2013). Circadian rhythms are 
generated by molecular feedback loops; tran-
scriptional activators induce the expression 
of genes that repress their own transcription 
(Lowrey and Takahashi, 2011). Disruption 
of circadian rhythms has been discussed as a 
possible risk factor of cancer. For example, 
epidemiological studies have suggested that 
working at night increases the risk of breast 
cancer (Kamdar et al., 2013). However, re-
cently a comprehensive study including 766 
breast cancer patients has been published 
that broadens our understanding of the role 
of the circadian clock system in breast cancer 
(Cadenas et al., 2014). The authors studied 
all known clock genes in relation to progno-
sis. Interestingly, loss of expression of circa-
dian clock genes in tumour tissue was asso-
ciated with a clearly higher risk to develop 
metastasis (Cadenas et al., 2014). Recently, 
numerous studies have been performed to 
identify prognostic genes in breast cancer 
(e.g. Sicking et al., 2014a, b; Siggelkow et 
al., 2012; Godoy et al., 2014; Schmidt et al., 
2008a, b; Cadenas, 2012; Cadenas et al., 
2010; Ghallab, 2014). However, loss of cir-
cadian clock genes seems to be of independ-
ent prognostic influence. The association of 
decreased circadian clock gene expression 
was also observed in different molecular 
subtypes of breast cancer (Desmedt et al., 
2007; Schmidt et al., 2008a, b, 2009) and 
was independent of established clinical fac-
tors. But the perhaps most interesting result 
of Cadenas et al. (2014) was obtained by 
pairwise analysis of functionally related 
clock genes. PER3 and CRY2 are proteins 
that form dimers acting as negative feedback 
regulators and are known to show similar 
oscillation patterns. Therefore, a strong cor-
relation between both genes can be anticipat-
ed. Indeed the authors observed strong corre-
lations between CRY2 and PER3 in well-
differentiated tumours that did not grow ag-
gressively (Cadenas et al., 2014). In contrast, 
the correlation between both clock genes was 
lost in more aggressive carcinomas. This 
breakdown of correlation between clock 
genes was also observed with loss of expres-
sion of the estrogen receptor, amplification 
of the oncogene HER2 and increasing histo-
logical grade (Cadenas et al., 2014). In con-
clusion, Cadenas and colleagues have clearly 
shown that loss of clock gene expression and 
particularly the breakdown of coordinated 
co-expression of clock genes is associated 
with worse prognosis and dedifferentiation, a 
feature so far unknown in breast cancer. 
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